eFFECTOR Therapeutics, Inc. (LWK1.SG)

9,25 0,00 (0,00%) Börsenschluss: 09:03AM CEST

eFFECTOR Therapeutics, Inc.

142 North Cedros Avenue
Suite B
Solana Beach, CA 92075
United States
858 925 8215
https://effector.com

Sektor(en): 
Branche: 
Vollzeitmitarbeiter: 14

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Davide Ruggero Ph.D.	Co-Founder and Member of Clinical & Scientific Advisory Board	N/A	N/A	N/A
Dr. Kevan M. Shokat Ph.D.	Co-Founder and Member of Clinical & Scientific Advisory Board	N/A	N/A	N/A

Die Beträge haben den Stand und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company's lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. The company has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E; and collaboration agreement with the Dana-Farber Cancer Institute on a Phase 2 clinical trial, evaluating Zotatifin as combination treatment in ER+ endometrial cancer and in low grade serous ovarian cancer. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.

Corporate Governance

eFFECTOR Therapeutics, Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.